Vericiguat added to optimized therapy in real-world HFrEF patients significantly reduced NT-proBNP (3532.0 to 2291.5 pg/mL, p<0.001) and increased LVEF (30.3% to 35.4%, p<0.001) at 1 year.
Observational (n=835)
Yes
Does vericiguat improve clinical, biochemical, and echocardiographic outcomes in patients with HFrEF following recent decompensation in a real-world setting?
In a real-world Spanish registry, adding vericiguat to highly optimized medical therapy in HFrEF patients following decompensation was associated with reverse remodeling, reduced NT-proBNP, and improved functional class over 1 year.
Abstract Aims To evaluate the effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction (HFrEF) following recent decompensation in routine clinical practice in Spain. Methods VERISEC is a prospective, multicenter registry of 835 consecutive patients initiating vericiguat at 41 centers in Spain. Functional class, biochemical markers, ventricular function, and clinical events were analyzed during 1-year follow-up. Results Patients (age 71.3 years SD: 11.2, 78.9% male) received highly optimized baseline therapy: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAASi, and 79.8% MRAs. Quadruple therapy remained stable (61.7% baseline to 63.0% at 12 months; p=0.526). At 1-year follow-up, significant improvements were observed. NT-proBNP decreased from 3532.0 (IQR: 1689.3–6974.5) to 2291.5 pg/mL (IQR: 1063.0–5076.3; p0.001) and LVEF increased from 30.3% (SD: 7.6) to 35.4% (SD: 11.1; p0.001). NYHA class improved, with class II patients increasing from 55.6% to 62.2% (p0.001). Mean HF decompensations requiring intravenous diuretics decreased from 1.34 (SD: 1.1) in the preceding year to 0.65 (SD: 1.3) during follow-up. Non-HF cardiovascular hospitalizations decreased from 0.98 (SD: 1.4) to 0.39 (SD: 1.0). Vericiguat was discontinued in 13.4% of patients, primarily due to symptomatic hypotension (49.4%). Higher baseline NT-proBNP (per 1000-pg/mL increase) independently predicted discontinuation (OR: 1.06; 95% CI: 1.03–1.08; p0.001). Conclusions Vericiguat added to optimized quadruple therapy was associated with reverse remodeling, reduced NT-proBNP, improved functional class, and a numerical reduction in HF-related events in real-world HFrEF patients. These findings confirm the clinical utility and safety of vericiguat in routine practice.
Esteban-Fernández et al. (Wed,) conducted a observational in Heart failure and reduced ejection fraction (HFrEF) following recent decompensation (n=835). Vericiguat was evaluated on Functional class, biochemical markers, ventricular function, and clinical events. Vericiguat added to optimized therapy in real-world HFrEF patients significantly reduced NT-proBNP (3532.0 to 2291.5 pg/mL, p<0.001) and increased LVEF (30.3% to 35.4%, p<0.001) at 1 year.